Loading articles...
ESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
The ESC Cardio-Oncology 2026 congress will address cardiotoxicity from cancer therapies, focusing on early detection and management strategies.
ADA 2026: Key Diabetes Trials to Watch
The upcoming ADA 2026 conference will feature pivotal trials in diabetes management, focusing on novel GLP-1 receptor agonists and SGLT2 inhibitors.
Disability Insurance: Essential Considerations for Medical Residents
Medical residents face unique challenges in securing disability insurance. Understanding policy types and key features is critical for financial protection.
CMS Adopts Performance-Based Standards for CRC Biomarker Tests
The Centers for Medicare & Medicaid Services (CMS) has implemented new performance-based standards for colorectal cancer (CRC) biomarker tests, despite ongoing questions regarding the clinical utility of some assays.
Professional Growth Through Purposeful Imbalance
Achieving professional growth in demanding medical fields may necessitate periods of 'purposeful imbalance' rather than strict work-life equilibrium.
FDA Clears OTC CGM for Non-Insulin-Using Children Aged 2+
The FDA has cleared an over-the-counter continuous glucose monitor for children aged 2 years and older who do not use insulin.
Purposeful Imbalance: A Strategy for Professional Growth
Achieving professional growth may necessitate a strategic, temporary deviation from conventional work-life balance, termed 'purposeful imbalance.'
Exercise Declined in Patients with Obesity After Starting a GLP-1
Patients with obesity showed reduced physical activity after initiating GLP-1 receptor agonists, according to a recent analysis.
GLP-1 Receptor Agonists Linked to Elevated Hypotension Risk
GLP-1 receptor agonists are associated with an increased incidence of hypotensive events, particularly in patients with pre-existing cardiovascular risk factors.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.